"Ultimately, if we
conclude a licensing deal with HA-Irinotecan, this may provide
us with additional flexibility to be creative in generating value from fondaparinux for our shareholders. We are therefore
aggressively pursuing these two initiatives and look forward to updating the market on progress as it is made"
SP going up on large volume, I would say someone knows something about a licensing deal. Though not yet final, they are taking a position.
"In the meantime, we are aggressively assessing strategic
options to best return value from fondaparinux to shareholders, including potential paths such as monetization, a return of capital to shareholders or a demerger of Audeo."
I am really disappointed that they are choosing to get rid of fonda. It may be good for the SP in the short term but I would prefer to see a company grow with their existing assets.
"we hope to see the benefits of reduced manufacturing costs for fondaparinux in 2014"
hopefully we get 15-20m profit in 2014.
- Forums
- ASX - By Stock
- TSN
- Ann: Annual Report to shareholders
Ann: Annual Report to shareholders , page-2
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable